Bionet
BIONET Corp. engages in the cell therapy business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells; and genetic testing services. It also provides storage and application of hematopoietic stem cells; regenerative medicine, analytical testing… Read more
Bionet - Asset Resilience Ratio
Bionet (1784) has an Asset Resilience Ratio of 38.62% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Bionet's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Bionet's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.20 Billion | 38.62% |
| Total Liquid Assets | NT$1.20 Billion | 38.62% |
Asset Resilience Insights
- Very High Liquidity: Bionet maintains exceptional liquid asset reserves at 38.62% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Bionet Industry Peers by Asset Resilience Ratio
Compare Bionet's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
|
Cytogen Inc
KQ:217330 |
Diagnostics & Research | 39.93% |
|
U2Bio Co., Ltd.
KQ:221800 |
Diagnostics & Research | 68.57% |
Annual Asset Resilience Ratio for Bionet (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Bionet.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 42.27% | NT$1.33 Billion | NT$3.16 Billion | +13.79pp |
| 2023-12-31 | 28.48% | NT$668.86 Million | NT$2.35 Billion | +13.40pp |
| 2022-12-31 | 15.08% | NT$277.20 Million | NT$1.84 Billion | +0.32pp |
| 2021-12-31 | 14.76% | NT$263.29 Million | NT$1.78 Billion | -0.32pp |
| 2020-12-31 | 15.08% | NT$261.59 Million | NT$1.73 Billion | -3.08pp |
| 2019-12-31 | 18.16% | NT$319.78 Million | NT$1.76 Billion | +0.20pp |
| 2018-12-31 | 17.96% | NT$320.20 Million | NT$1.78 Billion | -2.12pp |
| 2017-12-31 | 20.08% | NT$366.44 Million | NT$1.82 Billion | -- |